United Kingdom Vasomotor Symptoms Market Insight
United Kingdom Vasomotor Symptoms Market is growing at an 2.72% CAGR, driven by menopause awareness, aging population, and expanding hormonal
United Kingdom Vasomotor Symptoms Market Insights Forecasts to 2035
- The United Kingdom Vasomotor Symptoms Market Size Was Estimated at USD 156.23 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 2.72% from 2025 to 2035
- The United Kingdom Vasomotor Symptoms Market Size is Expected to Reach USD 204.33 Million by 2035
Notable Insights for United Kingdom Vasomotor Symptoms Market
- By treatment type, hormone replacement therapy (HRT) dominated, accounting for approximately 60% share in 2024, supported by broad clinical adoption for menopause symptom management.
- By drug class, neurokinin-3 receptor antagonists are expected to witness the fastest growth due to increasing adoption of about 67% Share, non-hormonal therapies for moderate-to-severe hot flashes.
- Approximately 75% of menopausal women experience vasomotor symptoms such as hot flashes and night sweats, increasing healthcare consultations across the UK.
- Around 45% of symptomatic women seek prescription or clinical treatment, while digital menopause platforms and telehealth services continue gaining traction.
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Vasomotor Symptoms Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Vasomotor Symptoms Market
- Pfizer
- Astellas Pharma
- Bayer
- Novo Nordisk
- Abbott
- Theramex
- Eli Lilly and Company
- GlaxoSmithKline
- Viatris
- Others
Recent Developments:
- In October 2025 – The UK menopause market is shifting toward personalized vasomotor symptom therapies, with growing adoption of targeted non-hormonal treatments and individualized hormone care for women experiencing moderate-to-severe hot flushes.
- In December 2023 – The MHRA licensed fezolinetant (Veoza), the UK’s first non-hormonal neurokinin-3 receptor antagonist for moderate-to-severe vasomotor symptoms, expanding menopause treatment options and improving symptom management outcomes.
Market Segmentation:
United Kingdom Vasomotor Symptoms Market, By Treatment Type
- Hormone Replacement Therapy (HRT)
- Non-Hormonal Therapy
- Combination Therapy
- Others
United Kingdom Vasomotor Symptoms Market, By Route of Administration
- Oral
- Injectable
- Transdermal
United Kingdom Vasomotor Symptoms Market, By End User
- Hospitals & Clinics
- Home Care Settings
- Specialty Gynecology Centers
United Kingdom Vasomotor Symptoms Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Channels
Expert Views:
The UK Vasomotor Symptoms Market is predicted to experience steady growth owing to heightened campaigns for increased menopause awareness, higher diagnosis rates, and growing consumer demands for tailored women’s health care solutions. It is important to note that the experts believe hormone-based treatment methods will continue their prevalence, whereas alternative neurokinin-targeted treatments without hormones are predicted to become increasingly popular amongst women seeking alternatives. Growth in telehealth services related to menopause, initiatives by the NHS, and ongoing innovations within the pharmaceutical industry are likely to support market growth through 2035.